EUCTR2013-003704-39-GB进行中（未招募）1 期
An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression - CV risk in HIV patients switching from a boosted PI to DTG
St Stephen's AIDS Trust0 个研究点目标入组 420 人开始时间: 2014年3月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Is male or female aged over 50, OR aged over 18 years with a Framingham risk score above 10%
- •2.Has documented HIV-1 infection
- •3.Has signed the Informed Consent Form voluntarily
- •4.Is willing to comply with the protocol requirements
- •5.Has been receiving an ARV regimen containing a boosted PI (darunavir, atazanavir, lopinavir, saquinavir, or fosamprenavir) plus 2NRTIs for >24 weeks
- •6.Has stable virological suppression (plasma HIV-RNA <50 copies/mL for >24 weeks)
- •7.If female and of childbearing potential, is using effective birth control methods (see appendix 4) and is willing to continue practising these birth control methods during the trial and for at least 2 weeks after the last dose of study medication. Note: Non-childbearing potential is defined as either post-menopausal (12 months of spontaneous amenorrhoea and =45 years) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy
- •8.If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 350
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1.Infected with HIV-2
- •2.Using any concomitant therapy disallowed as per the reference safety information and product labelling for the study drugs
- •3.Has acute viral hepatitis including, but not limited to, A, B, or C
- •4.Has chronic hepatitis B and/or C with AST and/or ALT >5 x ULN
- •Note: Subjects can enter trial with chronic HBV if HBV-DNA undetectable at screen (and no detectable result in last 6 months) and with chronic HCV if not expected to require treatment during the trial period.
- •5.Any investigational drug within 30 days prior to the trial drug administration
- •6.Any prior evidence of primary viral resistance (if a resistance test is available) based on the presence of any major resistance-associated mutation to backbone NRTI
- •7.History of prior virological failure, eg 2 consecutive HIV-1 RNA >50 c/ml -at or after week 32 following first ART initiation or confirmed rebound viraemia >200 copies/ml after having a VL of <50 copies/ml without resistance test (NOTE: Switch for toxicity or tolerability with wild type virus does not count as virological failure)
- •8.Dialysis or renal insufficiency (creatinine clearance < 50ml/min)
- •9.History of decompensated liver disease (AST or ALT=5x the upper limit of normal (ULN) or ALT = )3 x ULN and bilirubin = 1.5 x ULN with > 35% direct bilirubin.
- •10.Unstable liver disease (as defined by the presence of ascities, encephalopathy, coagulopathy, hypoalbuminemia, esophagael or gastic varices, or persistent jaundice), know biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones))
- •11.Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification (see appendix 5)
- •12.If female, currently pregnant or breastfeeding
- •13.Opportunistic infection within 4 weeks prior to first dose of DTG
- •14.Clinical decision that a switch of antiretroviral therapy should be immediate
- •15.Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
- •16.Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator’s opinion, interfere with assessments or completion of the trial.
- •17.History or presence of allergy to the study drug or their components
研究者
相似试验
进行中（未招募）
1 期
CV risk in HIV patients switching from a boosted PI to DTGEUCTR2013-003704-39-ITSt Stephen's AIDS Trust420
进行中（未招募）
1 期
Investigation on the effect and tolerability of erenumab in posttraumatic headachePost-traumatic headacheMedDRA version: 20.0Level: LLTClassification code 10019222Term: Headache post-traumaticSystem Organ Class: 100000004852EUCTR2018-003943-46-DKDanish Headache Center100
进行中（未招募）
1 期
An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea - STOP ROS StudyEUCTR2019-003971-20-DKRigshospitalet Glostrup30
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 18.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-ESRoche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd600
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-IEF. Hoffmann-La Roche Ltd680